The Prometheus League
Breaking News and Updates
- Abolition Of Work
- Ai
- Alt-right
- Alternative Medicine
- Antifa
- Artificial General Intelligence
- Artificial Intelligence
- Artificial Super Intelligence
- Ascension
- Astronomy
- Atheism
- Atheist
- Atlas Shrugged
- Automation
- Ayn Rand
- Bahamas
- Bankruptcy
- Basic Income Guarantee
- Big Tech
- Bitcoin
- Black Lives Matter
- Blackjack
- Boca Chica Texas
- Brexit
- Caribbean
- Casino
- Casino Affiliate
- Cbd Oil
- Censorship
- Cf
- Chess Engines
- Childfree
- Cloning
- Cloud Computing
- Conscious Evolution
- Corona Virus
- Cosmic Heaven
- Covid-19
- Cryonics
- Cryptocurrency
- Cyberpunk
- Darwinism
- Democrat
- Designer Babies
- DNA
- Donald Trump
- Eczema
- Elon Musk
- Entheogens
- Ethical Egoism
- Eugenic Concepts
- Eugenics
- Euthanasia
- Evolution
- Extropian
- Extropianism
- Extropy
- Fake News
- Federalism
- Federalist
- Fifth Amendment
- Fifth Amendment
- Financial Independence
- First Amendment
- Fiscal Freedom
- Food Supplements
- Fourth Amendment
- Fourth Amendment
- Free Speech
- Freedom
- Freedom of Speech
- Futurism
- Futurist
- Gambling
- Gene Medicine
- Genetic Engineering
- Genome
- Germ Warfare
- Golden Rule
- Government Oppression
- Hedonism
- High Seas
- History
- Hubble Telescope
- Human Genetic Engineering
- Human Genetics
- Human Immortality
- Human Longevity
- Illuminati
- Immortality
- Immortality Medicine
- Intentional Communities
- Jacinda Ardern
- Jitsi
- Jordan Peterson
- Las Vegas
- Liberal
- Libertarian
- Libertarianism
- Liberty
- Life Extension
- Macau
- Marie Byrd Land
- Mars
- Mars Colonization
- Mars Colony
- Memetics
- Micronations
- Mind Uploading
- Minerva Reefs
- Modern Satanism
- Moon Colonization
- Nanotech
- National Vanguard
- NATO
- Neo-eugenics
- Neurohacking
- Neurotechnology
- New Utopia
- New Zealand
- Nihilism
- Nootropics
- NSA
- Oceania
- Offshore
- Olympics
- Online Casino
- Online Gambling
- Pantheism
- Personal Empowerment
- Poker
- Political Correctness
- Politically Incorrect
- Polygamy
- Populism
- Post Human
- Post Humanism
- Posthuman
- Posthumanism
- Private Islands
- Progress
- Proud Boys
- Psoriasis
- Psychedelics
- Putin
- Quantum Computing
- Quantum Physics
- Rationalism
- Republican
- Resource Based Economy
- Robotics
- Rockall
- Ron Paul
- Roulette
- Russia
- Sealand
- Seasteading
- Second Amendment
- Second Amendment
- Seychelles
- Singularitarianism
- Singularity
- Socio-economic Collapse
- Space Exploration
- Space Station
- Space Travel
- Spacex
- Sports Betting
- Sportsbook
- Superintelligence
- Survivalism
- Talmud
- Technology
- Teilhard De Charden
- Terraforming Mars
- The Singularity
- Tms
- Tor Browser
- Trance
- Transhuman
- Transhuman News
- Transhumanism
- Transhumanist
- Transtopian
- Transtopianism
- Ukraine
- Uncategorized
- Vaping
- Victimless Crimes
- Virtual Reality
- Wage Slavery
- War On Drugs
- Waveland
- Ww3
- Yahoo
- Zeitgeist Movement
-
Prometheism
-
Forbidden Fruit
-
The Evolutionary Perspective
Category Archives: Transhuman News
How a ‘Velcro’ chip that traps alien DNA could improve prenatal testing – STAT
Posted: August 9, 2017 at 4:47 am
Why fentanyl is deadlier than heroin, in a single
Why fentanyl is deadlier than heroin, in a single photo
Allergan CEO looks smart for pledging to rein in
Allergan CEO looks smart for pledging to rein in prices. But will it make a difference?
The electrifying fitness technique that has doctors worried
The electrifying fitness technique that has doctors worried
Drug treatments didnt work. Can a simple diet help
Drug treatments didnt work. Can a simple diet help change these childrens lives?
After her own complicated delivery, lawmaker aims to address
After her own complicated delivery, lawmaker aims to address Texass alarming maternal death rate
White House rejects appeal to call national emergency over
White House rejects appeal to call national emergency over opioid epidemic
Go here to see the original:
How a 'Velcro' chip that traps alien DNA could improve prenatal testing - STAT
Posted in DNA
Comments Off on How a ‘Velcro’ chip that traps alien DNA could improve prenatal testing – STAT
Sacramento County Sheriff’s Department using new DNA technology for cold case – ABC10
Posted: at 4:47 am
Alexa Renee, KXTV 5:43 PM. PDT August 08, 2017
Investigators say Robin Brooks found dead 37 years ago was sexually assaulted prior to being stabbed to death in her apartment. (Photo: Sacramento County Sheriff's Department)
The Sacramento County Sheriff's Department is taking a crack at a cold case using an advanced DNA technology.
On April 24, 1980, Robin Gisela Brooks, was found stabbed to death in the bedroom of her Rosemont apartment. The 20-year-old had been sexually assaulted prior to her death and investigators found DNA evidence of the suspect at the crime scene but have been unable to identify the killer.
Brooks was scheduled to work at Donut Time on Kiefer Boulevard on the day she was found dead, but never show up for her shift. That's when coworkers came looking for Brooks and made the tragic discovery. Brooks family has a $10,000 reward for information leading to the arrest and conviction of the person responsible for her murder.
Her family may get closer to getting answers because of the sheriff's department new efforts in finding the suspect. The department has a full DNA profile of the suspect but no matches have come up on any federal or state DNA database.
Sacramento County investigators are hoping DNAphenotypingcould paint a picture of who killed Brooks. The DNA service cost the department $4,000 and is charged per case, it's not a flat rate fee. It's the first time the sheriff's department has used DNA phenotypingto try and solve a case.
What is DNA phenotyping?
Phenotyping can also help identify relatives of a person through DNA connections.
The testing cannot determine factors such as age, weight and facial hair since those details are not available in a person's genetic code. Parabonpredicts a person at 25-years-old by default. Forensic artists would have to adjust age, facial hair and weight based on description information provided by police or eye witnesses.
DNA phenotyping helps illustrate what a person may look like when there are no leads on identification or when a DNA profile doesn't match anything in a database. The tool is especially helpful in case like the Brooks murder, where there were no eyewitnesses to the crime to describe a suspect, but traces of DNA were left behind.
The technology was created fordefense, security, justice, and intelligence communities and has been used by numerous agencies to help generate leads. Private citizens have used Snapshot to find ancestry information.
Has DNA phenotyping helped solve cases?
Phenotyping can be a great tool for eliminating suspects and sparking leads.
Police had previously believed the suspect was a Latino male because Bouzigard was last seen with a group of Latino men. However, the Parabonanalysis found the suspect to be a white male.
Parabon led the Rockingham County Sheriff's Office to Jose Alvarez Jr., the brother of couple's daughter's boyfriend at the time of the murder. He was arrested in Aug. 2015 and later pled guilty to two both murders. In July of 2016, he was sentenced to two consecutive life sentences without the possibility of parole.
Phenotyping can also help with unidentified remains when there is no visual on what the person may have looked like.
What are the issues with DNAphenotyping?
Phenotypingrelies on identifying using physical appearance, which is a method that can run into some problems. Parabontechnology cannot positively create a photo ID of a person, it can only help create a visual when there are no other leads.
Also, a person can look like a sibling or relative, or even another completely unrelated person. There's no science available that can confirm a person's DNA through face structure.
The only way to identify someone using DNA phenotypingis if a person of interest is tested for DNA and it comes back as a match with the sample used to create the Parabonsketch. This means, there'd have to be a tip leading to that person. Unfortunately, the actual suspect may not look like the sketch and misleading tips may come in.
Another issue the ACLU touches on is social and racial profiling. When a sketch is that of a person of color it can fuel "existing societal prejudices to further increase the risks to innocent people". Also, police officers with less sophisticated science tools may rely too heavily on the images and pressure DNA tests from innocent people.
Phenotypingshould be used as more of a tool to narrow down or eliminate suspects, rather than as a point of probable cause to "create" a suspect.
In cold cases such as the killing of Brooks, phenotypingcan help jog memories of someone who may have seen something or knows anything about the suspect, since there is nothing else to go on to solve the case but the DNA profile of the suspect.
Below are the Snapshot DNA phenotyping results for the suspect in the Brooks case. Note physical appearance of subject may have changed over the years.
Snapshot prediction of suspect in 1980 murder of Rosemont woman, Robin Grisela Brooks. (Photo: Parabons NanoLabs Inc.)
Snapshot prediction of suspect in 1980 murder of Rosemont woman, Robin Grisela Brooks. (Photo: Parabons NanoLabs Inc.)
2017 KXTV-TV
Read more:
Sacramento County Sheriff's Department using new DNA technology for cold case - ABC10
Posted in DNA
Comments Off on Sacramento County Sheriff’s Department using new DNA technology for cold case – ABC10
NIH accelerates the use of genomics in clinical care – National Institutes of Health (press release)
Posted: at 4:46 am
National Institutes of Health (press release) | NIH accelerates the use of genomics in clinical care National Institutes of Health (press release) The National Institutes of Health (NIH) is awarding $18.9 million towards research that aims to accelerate the use of genome sequencing in clinical care. The new awards will generate innovative approaches and best practices to ensure that the ... NIH accelerates genomics in clinical healthcare |
See more here:
NIH accelerates the use of genomics in clinical care - National Institutes of Health (press release)
Posted in Genome
Comments Off on NIH accelerates the use of genomics in clinical care – National Institutes of Health (press release)
TOM PURCELL: Too much of a good thing? – The Daily Freeman
Posted: at 4:46 am
A 125-year life expectancy for human beings? I have zero desire to stick around that long.
Ah, yes, you speak of a debate among scientists over human longevity. I read about it at Business Insider. Some scientists argue that the maximum age humans may live is 115 years, whereas others argue that 125 years is possible.
A hundred and twenty-five years of watching Republicans and Democrats going at it? The heck with that.
Living is rife with challenges, to be sure. But living a long life has its upsides. Wouldnt you want to visit your parents and other family members for a lot more years than most of us are able? Wouldnt you like to see them all at a Sunday dinner several more times than most human beings are able?
Advertisement
Maybe with your family. My family has taken years off of my life!
I see, but wouldnt it be awesome if some of our finest human beings could stick around longer? Don Rickles, one of the greatest entertainers ever, died this year at 91. How great would it be to keep him around for two more decades?
True, but if Rickles were to stick around longer, that means annoying celebrities would stick around, too, and keep yapping at us every time a Republican becomes president.
There are other upsides to a longer life. What if we could keep our greatest minds around longer? Where would the world be if Einstein had another 25 years to unlock the mysteries of the universe?
But what if he figured out ways to extend human life even further, which would require me and the wife to have to keep coming up with new things to bicker about? Who has that kind of energy?
The downsides are a fair point. As people live longer, they could overburden government programs, such as Social Security. Where would we get all the money to support them?
How about we especially extend the lives of the rich so we can take them to the cleaners?
And living is expensive. If you live to 125, how will you pay for your housing and food and everyday expenses?
Thank goodness McDonalds is always hiring, but I for one have no desire to flip burgers at the age of 125.
The costs of medical care are too high for millions now. I imagine that at 125 years of age, ones medical bills would be difficult to manage.
Look, as a middle-aged guy, who is already showing signs of fatigue, here is what I know about living. Life is largely made up of colds, bills, speeding tickets and people who let you down. These experiences are connected together by a series of mundane tasks.
Did anyone tell you how cheerful you can be? Go on.
Well, these drudgeries are occasionally interrupted by a wonderful meal, a really good laugh with friends or a romantic evening with a lovely woman. Then the mundane stuff starts all over again. Who wants 125 years of that?
A lot of people do. The human lifespan has improved significantly in the past few generations. Millions are living healthy lives beyond the age of 80 today, and, when they were younger, few of them expected to live that long. Why not live relatively good lives until 125?
Because then Id really worry about my slacker son.
Why?
Hes 35 years old and still living at home. If we drastically extend lifespans, my wife will have to tell him: Son, youre 100 years old! When are you going to move out of the basement and get a job?
Tom Purcell is syndicated by Cagle Cartoons Inc. Readers may write to him via email at Tom@TomPurcell.com.
See the original post:
TOM PURCELL: Too much of a good thing? - The Daily Freeman
Posted in Human Longevity
Comments Off on TOM PURCELL: Too much of a good thing? – The Daily Freeman
Do Sharks Hold the Secret to Longevity? – Anti Aging News
Posted: at 4:46 am
1091 0 Posted on Aug 08, 2017, 5 a.m.
New study finds that the exceptionally long lifespan of the Greenland shark may provide clues to extending human lifespan.
About Greenland Sharks
Greenland sharks are considered the longest living vertebrates. A team of scientists led by Julius Nielson, a marine biologist from the University of Copenhagen, used radiocarbon dating on 28 Greenland sharks. They established that one of the female sharks was approximately 392 years.
Research Surrounding the Greenland Sharks
The longevity of the Greenland sharks has stirred interest in the research world. Scientists have worked towards identifying the genes responsible for this unique trait.
Could these genes be used to extend the lifespan of human beings? Scientists believe that a successful identification and extraction of the genes could be a major milestone in achieving longevity among human beings.
Researchers at the University of Exeter have studied almost 100 Greenland sharks. They have sequenced their mitochondrial genome. The achievement set an excellent stage for researchers to scrutinize the sequence and understand the reason behind the shark's longevity.
Prof Kim Praebel, the lead scientist of the research, explained why the research is vital. He noted that unraveling the secrets behind the Green shark's longevity may tremendously boost the efforts on the improvement of humans' lifespan.
Why is the Study of Greenland Sharks Important?
Discovery of the genes responsible for longevity in Greenland sharks would be a vital achievement in the research world. It would explain the limited life spans in almost all the vertebrates. Additionally, the discovery would allow the scientists to study whether the genes can be used to prolong the life of the human beings.
The research at the University of Exeter found out that the Greenland sharks swim long distances across the Atlantic Ocean. They discovered that they mate in the deeply hidden fjords of the Arctic. This realization is instrumental in uncovering the negative effects of the activities of human beings on aquatic life. The study of the tissues and the bones of the animal forms genetic data that is crucial in determining when contaminants and chemicals from industries started affecting the marine. The findings would be of considerable benefit to the environment and marine life protection.
The findings of this research have been presented in various forums including the Fisheries Society of the British Isles symposium. The scientists hope that the findings will boost the conservation efforts of the Greenland shark species and other wildlife in the ecosystem.
Excerpt from:
Do Sharks Hold the Secret to Longevity? - Anti Aging News
Posted in Human Longevity
Comments Off on Do Sharks Hold the Secret to Longevity? – Anti Aging News
An extra dose of this longevity hormone helped make mice smarter … – Popular Science
Posted: at 4:46 am
Klotho, in ancient Greek mythology, is one of the Fates controlling the span of human destiny tasked as she was with cutting the string that determined the length of a persons life. Klotho is also a naturally occurring hormone in the body. More than two decades ago, Japanese researchers discovered that this hormone plays a role in aging. People with more klotho in their body, tend to live longer and to retain more of their facultiesthat is to stay sharpwell into old age.
There are many elderly people who walk around and have completely normal, sharp vibrant brain function despite the fact that they are much older and the fact that they have a lot of disease toxins in the brain, Dr. Dena Dubal a neurobiologist at the University of California, San Franciscos Memory and Aging Center told Popular Science.
Dubal is the author on a study released today in the journal Cell Reports that looks at what happens to brain function when you inject klotho protein into mice.
Aging researchers like Dubal arent interested in extending life for its own sakethey dont have a Methuselah complexbut rather because aging is the biggest factor for disease. If they can find a way to slow aging, or at least its effects, they might find a way to allow us to avoid the cognitive declines, and diseases such as stroke, heart disease, and diabetes that tend to come as we flip through more pages on the calendar.
A few years ago, we discovered in collaboration with several people that in human populations those people that had higher levels of klotho had better cognitive functions in normal aging, says Dual.
Which is great if you happen to be genetically blessed with higher levels of klotho, less great if youre not.
Earlier studies have looked at the impacts of klotho on longevity and health, including brain health, but they tended to rely on genetically modified mice. The genes of these mice had been modified to allow them to produce more klotho or less.
Those studies found that mice modified to produce more klotho lived longer, which is promising. But despite recent advances, genetically modifying humans is still an ethical minefield away in the future, especially if the modifications are being made to improve wellbeing as opposed to preventing disease. And, genetically altering embryos might help future populations, but it doesnt do much for those of us already living. So, Dubal wanted to see is if mice injected with klothoacting essentially a hormonal supplementwould show cognitive improvements.
The answer, seems to be yes.
To get the result, Dubal and her colleagues injected three types of mice with a portion of the protein. They injected young mice, aged mice, and mice genetically altered to have brains similar to that which we would see in Alzheimers or Parkinsons patients in humans.
Within hours they showed better cognitive function, says Dubal.
Since you cant exactly administer a mouse an IQ test, they assessed brain power based on the mices ability to navigate a series of water mazes, in an experiment that sounds on par with human a trip to Wisconsins famed waterslide park, The Dells.
They found that mice that had daily injections and were better able to navigate the maze (as measured by the distance traveled to find a hidden platform) than their control group peers. In a classic example of work smarter, not harder, the klotho mice were just much more efficient seekers.
We tested them two weeks later in a different cognitive test and they were still smarter, says Dubal, which suggested that getting the klotho protein into their bodies combined with brain training and stimulation had a long-lasting effect in their brain. Because the half-life of the protein is only seven and a half hours long, any of the protein should have been long out of their system.
There are a few caveats.
First, this was an experiment in micenot in humans. While its incredibly promising, the study results are short term and they werent looking for side effects. The pace at which a promising scientific study is turned into a supplement of dubious efficacy is stunning these days, so please dont subject yourself to some back-alley klotho injection. Between resveratrol and superfoods weve been there before.
At the same time, we know that klotho levels can be affected not only by genetics - but also by stress. If you want to help your body keep its klotho levels at your own peak you might want to try proven stress reduction techniques like exercise and chilling out about your own impending mortality.
Finally, the researchers arent sure how klotho seems to be generating this effect because the protein is too big to pass from the body into the brain. For a long time, weve studied the brain in isolation from the body with the brain mostly telling the body what to do, and the body acting like a series of censors that give the brain useful data. But this study like our growing understanding of the connection between our microbiome and brain health, and exercise and brain health, this study touches on our growing understanding of how the body connects to the brain to help make the brain more resilient.
Read the original:
An extra dose of this longevity hormone helped make mice smarter ... - Popular Science
Posted in Human Longevity
Comments Off on An extra dose of this longevity hormone helped make mice smarter … – Popular Science
Dermira Commits $135M for Global Rights to Roche Eczema Drug – Xconomy
Posted: at 4:46 am
Xconomy San Francisco
Skin treatments developer Dermira is adding another experimental drug to its pipeline that it plans to test as a potential treatment for eczema, through a deal announced this morning with healthcare giant Roche.
But in picking up the global rights to lebrikizumab, Menlo Park, CA-based Dermira (NASDAQ: DERM) is entering a suddenly crowded field of new treatments for the skin condition, which is characterized by inflamed, itchy, and scaly rashes on the skin. Dermira has agreed to pay Roche $80 million now, plus $55 million next year for global rights to the drug. If Dermira can hit development and regulatory goals for the lebrikizumab, the company could be on the hook to pay Roche up to $250 million more.
Should Dermira commercialize the injectable drug in other diseases, the company would have to pay more than $1 billion as the drug hits undisclosed sales marks. Dermira would also need to pay Roche royalties on the drugs sales. Roche is keeping the rights to the drug in interstitial lung diseases, a group of disorders that lead to progressive scarring of the lungs.
Eczema, also known as atopic dermatitis, is an autoimmune disorder that produces an inflammatory response thats visible on the skin. The condition affects at least 28 million people in the United States, according to the American Academy of Dermatology. Lebrikizumab is a monoclonal antibody drug that targets interleukin 13, a protein associated with inflammation.
Other pharmas are aiming to address the eczema market with new drugs. Last December, the FDA approved Pfizers (NYSE: PFE) topical ointment crisaborole (Eucrisa) as a treatment for mild-to-moderate eczema. That drug, which blocks the inflammatory enzyme PDE4, came to Pfizer through its $5.2 billion acquisition of Anacor Pharmaceuticals last year. Meanwhile, Tarrytown, NY-based Regeneron Pharmaceuticals (NASDAQ: REGN) received FDA approval in March for its moderate-to-severe eczema drug dupilumab (Dupixent). Like the Roche drug, dupilumab targets interleukin 13.
Dermira and Roche expect to close the licensing deal later this quarter. In early 2018, Dermira plans to start a Phase 2b dose-ranging study, enrolling patients who have moderate-to-severe eczema. The goal of the trial is to find the best dose for a larger Phase 3 clinical trial. Dermira said it expects that it will spend approximately $200 million to get the early results for the Phase 2b study.
Photo by Flicker user Oregon State Universityvia a Creative Commons license.
Frank Vinluan is editor of Xconomy Raleigh-Durham, based in Research Triangle Park. You can reach him at fvinluan [at] xconomy.com
See more here:
Dermira Commits $135M for Global Rights to Roche Eczema Drug - Xconomy
Posted in Eczema
Comments Off on Dermira Commits $135M for Global Rights to Roche Eczema Drug – Xconomy
Dermatologists collaborate on data-driven pediatric psoriasis research – ModernMedicine
Posted: at 4:45 am
Emerging research from an international dataset of pediatric psoriasis patients is revealing much needed information about how children fare with commonly used systemic treatments, says dermatologist Amy S. Paller, M.D., M.S.
And she says the collaborative effort is powered by pediatric dermatologists not industry.
Dr. Paller, professor and chair of dermatology at Northwestern University Feinberg School of Medicine and pediatric dermatologist at Ann and Robert H. Lurie Childrens Hospital of Chicago, presented findings from the PeDRA-EPPWG Study of Systemic Therapy in Pediatric Psoriasis at the July World Congress of Pediatric Dermatology in Chicago. She not only talked about the soon-to-be-published studys findings, but also how a retrospective analysis could inform a prospective registry.
Dr. Paller and colleagues launched the Pediatric Dermatology Research Alliance, or PeDRA, in 2012, recognizing that pediatric dermatologists needed to work as a group to research dermatologic conditions in children because many of the conditions are rare and lack pediatric-specific data.
Thats exactly what has happened in this work with pediatric psoriasis, Dr. Paller says.
Colleagues in the European Pediatric Psoriasis Working Group, or EPPWG were willing to buy in. The groups shared goals to better understand dermatologists experiences with systemic drugs for pediatric psoriasis, and to get experience with a joint registry, which hopefully would pave the way for a prospective pediatric psoriasis registry, according to Dr. Paller.
Ten centers from PeDRA in North America and 10 centers in Europe came together to perform the study.
It was a tremendous learning experience about some of the challenges of retrospective data collection and the benefit to prospective research using common data collection, Dr. Paller says.
The researchers extracted 54 different items from charts of patients treated with systemic therapy or phototherapy, but only allowed patients to be included who had at least a minimum dataset that could provide important information on demographics, clinical characteristics and severity, systemic agents used, treatment duration and efficacy, side effects and reasons for discontinuation of medications.
A review of thousands of patient records revealed 446 which met criteria for the minimal dataset; of those, 390 involved systemic therapy for pediatric psoriasis. In this joint PeDRA-EPPWG study, which was funded by the International Psoriasis Council, data was collected using the Research Electronic Data Capture, or REDCap, web-based data capture tool.
Excerpt from:
Dermatologists collaborate on data-driven pediatric psoriasis research - ModernMedicine
Posted in Psoriasis
Comments Off on Dermatologists collaborate on data-driven pediatric psoriasis research – ModernMedicine
Gene Therapy Is Now Available, but Who Will Pay for It? – Scientific American
Posted: at 4:45 am
By Ben Hirschler
LONDON (Reuters) - The science of gene therapy is finally delivering on its potential, and drugmakers are now hoping to produce commercially viable medicines after tiny sales for the first two such treatments in Europe.
Thanks to advances in delivering genes to targeted cells, more treatments based on fixing faulty DNA in patients are coming soon, including the first ones in the United States.
Yet the lack of sales for the two drugs already launched to treat ultra-rare diseases in Europe highlights the hurdles ahead for drugmakers in marketing new, extremely expensive products for genetic diseases.
After decades of frustrations, firms believe there are now major opportunities for gene therapy in treating inherited conditions such as haemophilia. They argue that therapies offering one-off cures for intractable diseases will save health providers large sums in the long term over conventional treatments which each patient may need for years.
In the past five years, European regulators have approved two gene therapies - the first of their kind in the world, outside China - but only three patients have so far been treated commercially.
UniQure's Glybera, for a very rare blood disorder, is now being taken off the market given lack of demand.
The future of GlaxoSmithKline's Strimvelis for ADA-SCID - or "bubble boy" disease, where sufferers are highly vulnerable to infections - is uncertain after the company decided to review and possibly sell its rare diseases unit.
Glybera, costing around $1 million per patient, has been used just once since approval in 2012. Strimvelis, at about $700,000, has seen two sales since its approval in May 2016, with two more patients due to be treated later this year.
"It's disappointing that so few patients have received gene therapy in Europe," said KPMG chief medical adviser Hilary Thomas. "It shows the business challenges and the problems faced by publicly-funded healthcare systems in dealing with a very expensive one-off treatment."
These first two therapies are for exceptionally rare conditions - GSK estimates there are only 15 new cases of ADA-SCID in Europe each year - but both drugs are expected to pave the way for bigger products.
The idea of using engineered viruses to deliver healthy genes has fuelled experiments since the 1990s. Progress was derailed by a patient death and cancer cases, but now scientists have learnt how to make viral delivery safer and more efficient.
Spark Therapeutics hopes to win U.S. approval in January 2018 for a gene therapy to cure a rare inherited form of blindness, while Novartis could get a U.S. go-ahead as early as next month for its gene-modified cell therapy against leukaemia - a variation on standard gene therapy.
At the same time, academic research is advancing by leaps and bounds, with last week's successful use of CRISPR-Cas9 gene editing to correct a defect in a human embryo pointing to more innovative therapies down the line.
Spark Chief Executive Jeffrey Marrazzo thinks there are specific reasons why Europe's first gene therapies have sold poorly, reflecting complex reimbursement systems, Glybera's patchy clinical trials record and the fact Strimvelis is given at only one clinic in Italy.
He expects Spark will do better. It plans to have treatment centers in each country to address a type of blindness affecting about 6,000 people around the world.
Marrazzo admits, however, there are many questions about how his firm should be rewarded for the $400 million it has spent developing the drug, given that healthcare systems are geared to paying for drugs monthly rather than facing a huge upfront bill.
A one-time cure, even at $1 million, could still save money over the long term by reducing the need for expensive care, in much the same way that a kidney transplant can save hundreds of thousands of dollars in dialysis costs.
But gene therapy companies - which also include Bluebird Bio, BioMarin, Sangamo and GenSight - may need new business models.
One option would be a pay-for-performance system, where governments or insurers would make payments to companies that could be halted if the drug stopped working.
"In an area like haemophilia I think that approach is going to make a ton of sense, since the budget impact there starts to get more significant," Marrazzo said.
Haemophilia, a hereditary condition affecting more than 100,000 people in markets where specialty drugmakers typically operate, promises to be the first really big commercial opportunity. It offers to free patients from regular infusions of blood-clotting factors that can cost up to $400,000 a year.
Significantly, despite its move away from ultra-rare diseases, GSK is still looking to use its gene therapy platform to develop treatments for more common diseases, including cancer and beta-thalassaemia, another inherited blood disorder.
Rivals such as Pfizer and Sanofi are also investing, and overall financing for gene and gene-modified cell therapies reached $1 billion in the first quarter of 2017, according to the Alliance of Regenerative Medicine.
Shire CEO Flemming Ornskov - who has a large conventional haemophilia business and is also chasing Biomarin and Spark in hunting a cure for the bleeding disorder - sees both the opportunities and the difficulties of gene therapy.
"Is it something that I think will take market share mid- to long-term if the data continues to be encouraging? Yes. But I think everybody will have to figure out a business model."
Visit link:
Gene Therapy Is Now Available, but Who Will Pay for It? - Scientific American
Posted in Gene Medicine
Comments Off on Gene Therapy Is Now Available, but Who Will Pay for It? – Scientific American
Here’s Why Editas Medicine Rose as Much as 15.9% Monday – Madison.com
Posted: at 4:45 am
What happened
Shares of gene editing leader Editas Medicine (NASDAQ: EDIT) rose nearly 16% Monday on heavy trading volume, most of which occurred shortly after the market opened. The number of shares traded in the first few minutes of trading exceeded the daily average trading volume.
There was no major announcement. Instead, Editas Medicine decided to payoff a promissory note issued to the Broad Institute, the holder of its gene editing patents, by issuing shares of common stock on Friday, Aug. 4 that became the property of the research institution. The maximum conversion price was $21.49 per share, which was significantly higher than the recent stock price, and it appears the shares were sold Monday morning at that higher price. Therefore, the company's stock received a little boost.
Despite the honest explanation with almost no significance to Editas Medicine (it didn't receive proceeds from issuing the shares to the Broad Institute), the gains managed to stick around. As of 3:21 p.m. EDT, the stock had settled to a 10.6% gain.
Image source: Getty Images.
In early March, Editas Medicine granted the Broad Institute and Wageningen University promissory notes worth 800,000 shares of common stock related to licensing fees for specific gene editing patents. The notes were convertible to shares at the company's discretion or after 150 days. Since early August is about 150 days after early March, it appears the latter took place.
It's worth pointing out that the Broad Institute was issued 271,347 shares of common stock a few days ago. That's substantially less than the 800,000 shares spelled out in the March filing. However, it's not easy to tell if the balance was given to others named in the filing or if the research institution negotiated a lower payment from Editas Medicine.
Either way, the fact that the Broad Institute unloaded its shares from the converted promissory note is hardly worrisome. After all, the research institution is simply realizing a licensing fee from Editas Medicine. Monday's pop is nothing more, nothing less.
Sometimes there are simple reasons for major stock movements. That is certainly the case with Editas Medicine stock on Monday. But there's good news for investors hoping that more actionable events were the driver of Monday's pop: The gene editing pioneer announces second-quarter 2017 earnings this Wednesday, Aug. 9. That should provide more timely information for shareholders that cannot get enough updates.
10 stocks we like better than Editas Medicine
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Editas Medicine wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of August 1, 2017
Maxx Chatsko has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Original post:
Here's Why Editas Medicine Rose as Much as 15.9% Monday - Madison.com
Posted in Gene Medicine
Comments Off on Here’s Why Editas Medicine Rose as Much as 15.9% Monday – Madison.com